IBT
STML

International Biotechnology Trust’s Stemline Therapeutics, Inc. STML Stock Holding History

International Biotechnology Trust’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-965,245
Closed -$10.3M – 70
2019
Q4 		$10.3M Buy
965,245
+130,000
+16% +$1.29M 3.69% 9
2019
Q3 		$8.7M Buy
835,245
+91,000
+12% +$1.19M 4.02% 8
2019
Q2 		$11.4M Sell
744,245
-52,000
-7% -$752K 4.23% 8
2019
Q1 		$10.2M Buy
796,245
+210,315
+36% +$2.38M 3.78% 4
2018
Q4 		$4.37M Hold
585,930
– – 2.71% 14
2018
Q3 		$7.46M Buy
585,930
+93,000
+19% +$1.49M 3.55% 9
2018
Q2 		$7.86M Hold
492,930
– – 3.02% 13
2018
Q1 		$7.52M Hold
492,930
– – 2.93% 13
2017
Q4 		$7.69M Buy
492,930
+310,000
+169% +$4.15M 2.71% 13
2017
Q3 		$2.03M Sell
182,930
-270,070
-60% -$2.54M 0.79% 34
2017
Q2 		$4.17M Buy
453,000
+123,000
+37% +$1.03M 1.58% 21
2017
Q1 		$2.81M Buy
+330,000
New +$3.01M 1.07% 26

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

International Biotechnology Trust's STML Position: Q1 2020 in Review

International Biotechnology Trust sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 965,245 shares — an estimated $10.3M sold.

International Biotechnology Trust first reported a position in STML in Q1 2017 and held it in 12 quarters. The position peaked at $11.4M in Q2 2019. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

  • International Biotechnology Trust reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • International Biotechnology Trust sold 965,245 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $10.3M.
  • International Biotechnology Trust first reported a position in Stemline Therapeutics, Inc. in Q1 2017 and held it in 12 quarters.
  • International Biotechnology Trust's Stemline Therapeutics, Inc. position peaked at $11.4M in Q2 2019.
  • 94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on International Biotechnology Trust's 13F filing for Q1 2020, filed 18 May 2020.